COMP <GO>
MEDS vs JNJ // GROSS PROFIT MARGIN
DataMeds AI Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MEDS 1
— JNJ 7
▲ GROSS PROFIT MARGIN LEADER: JNJ
LAST: $2.03 (-7.73%) • MKT CAP: $9.8M
gross-margins
-27.50%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MEDS VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MEDS | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | -27.50% | 67.90% | -95.40 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 28.70% | 6.00% | +22.70 | MEDS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 8/9 | -6.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.9 | 62.1 | -23.18 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.8M | $662.49B | -$662.48B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MEDS REV | JNJ REV | MEDS GROSS % | JNJ GROSS % | MEDS FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $23.3M | $94.19B | -27.5% | 67.9% | -$10.9M | $19.70B |
| FY 2024 | $18.1M | $88.82B | 9.7% | 69.1% | -$1.2M | $19.84B |
| FY 2023 | $0 | $85.16B | — | — | -$349.1K | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MEDS // BETA —
JNJ // BETA 1.08